Published in Health and Medicine Week, August 15th, 2005
The U.S. Food and Drug Administration (FDA) is currently reviewing the company's responsive gel implant and its cohesive gel implant (BioDimensional Style 410 Matrix) premarket approval applications (PMAs).
After consideration of the outcome of the April, 2005, FDA Advisory Panel meeting and in consultation with the FDA, the company modified its responsive gel PMA by separating data for eight round and the shaped Style 153 investigational devices. This PMA modification also included new 10-12 year...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.